<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2401233154
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEUKAST 4 mg Granules
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MONTELUKAST SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Granules
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Sachet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        77.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03DC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Leukast is a leukotriene receptor antagonist that blocks substances called leukotrienes.</p><p><strong>How Leukast works</strong></p><p>Leukotrienes cause narrowing and swelling of airways in the lungs. By blocking leukotrienes, Leukast improves asthma symptoms and helps control asthma.</p><p><strong>When Leukast should be used</strong></p><p>Your doctor has prescribed Leukast to treat your child&rsquo;s asthma, preventing asthma symptoms during the day and night.</p><ul><li>&nbsp;&nbsp; &nbsp;Leukast is used for the treatment of 6 months to 5 year old patients who are not adequately controlled on their medication and need additional therapy.</li><li>&nbsp;&nbsp;&nbsp; Leukast may also be used as an alternative treatment to inhaled corticosteroids for 2 to 5 year old patients who have not recently taken oral&nbsp; &nbsp; &nbsp; &nbsp; corticosteroids for their asthma and have shown that they are unable to use inhaled corticosteroids.</li><li>&nbsp; &nbsp;&nbsp;Leukast also helps prevent the narrowing of airways triggered by exercise for patients 2 years of age and older.</li></ul><p>Your doctor will determine how Leukast should be used depending on the symptoms and severity of your child&#39;s asthma.</p><p><strong>What is asthma?</strong></p><p>Asthma is a long-term disease.</p><p>Asthma includes:</p><ul><li>&nbsp; &nbsp; &nbsp; difficulty breathing because of narrowed airways. This narrowing of airways worsens and improves in response to various conditions.</li><li>&nbsp; &nbsp; &nbsp; &nbsp;sensitive airways that react to many things, such as cigarette smoke, pollen, cold air, or exercise.</li><li>&nbsp; &nbsp; &nbsp; &nbsp;swelling (inflammation) in the lining of the airways.</li></ul><p>Symptoms of asthma include: Coughing, wheezing, and chest tightness</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor about any medical problems or allergies your child has now or has had.</p><p><strong>Do not give Leukast to your child</strong></p><p>if he/she is allergic to montelukast or any of the other ingredients of this medicine (listed in section 6).</p><p><strong>Warnings and Precautions</strong></p><p>Talk to your doctor or pharmacist before you give Leukast to your child.</p><ul><li>&nbsp; &nbsp;&nbsp;If your child&rsquo;s asthma or breathing gets worse, tell your doctor immediately.&nbsp;</li><li>&nbsp; &nbsp;&nbsp;Oral Leukast is not meant to treat acute asthma attacks. If an attack occurs, follow the instructions your doctor has given you for your child. Always have your child&rsquo;s inhaled rescue medicine for asthma attacks with you.</li><li>&nbsp; &nbsp;&nbsp;It is important that your child take all asthma medications prescribed by your doctor. Leukast should not be used instead of other asthma medications your doctor has prescribed for your child.</li><li>&nbsp; &nbsp;&nbsp;If your child is on anti-asthma medicines, be aware that if he/she develops a combination of symptoms such as flu-like illness, pins and needles or numbness of arms or legs, worsening of pulmonary symptoms, and/or rash, you should consult your doctor.</li><li>&nbsp; &nbsp; &nbsp;Your child should not take acetyl-salicylic acid (aspirin) or anti-inflammatory medicines (also known as non-steroidal anti-inflammatory drugs or NSAIDs) if they make his/her asthma worse.</li></ul><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children less than 6 months of age.</p><p>There are different form(s) of this medicine available for pediatric patients under 18 years of age based on age range.</p><p><strong>Other medicines and Leukast</strong></p><p>Tell your doctor or pharmacist if your child is taking or has recently been given or might be given any other medicines including those obtained without a prescription.</p><p>Some medicines may affect how Leukast works, or Leukast may affect how your child&#39;s other medicines work.</p><p>Tell your doctor if your child is taking the following medicines before starting Leukast:</p><ul><li>&nbsp; &nbsp; &nbsp; phenobarbital (used for treatment of epilepsy)</li><li>&nbsp; &nbsp; &nbsp; &nbsp;phenytoin (used for treatment of epilepsy)</li><li>&nbsp; &nbsp; &nbsp; &nbsp;rifampicin (used to treat tuberculosis and some other infections).</li></ul><p><strong>Leukast with food and drink</strong></p><p>Leukast granules can be taken without regard to the timing of food intake.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>This subsection is not applicable for the Leukast 4 mg granules since they are intended for use in children 6 months to 5 years of age.</p><p><strong>Driving and using machines</strong></p><p>This subsection is not applicable for the Leukast 4 mg granules since they are intended for use in children 6 months to 5 years of age, however the following information is relevant to the active ingredient, montelukast.</p><p>montelukast is not expected to affect your ability to drive a car or operate machinery. However, individual responses to medication may vary. Certain side effects (such as dizziness and drowsiness) that have been reported with montelukast may affect some patients&rsquo; ability to drive or operate machinery.</p><p><strong>Leukast contains Mannitol which may </strong>have a mild laxative effect</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always have your child take this medicine exactly as your doctor or pharmacist has told you. Check with your child&#39;s doctor or pharmacist if you are not sure.</p><ul><li>&nbsp; &nbsp; &nbsp; This medicine is to be given to a child under adult supervision. Your child should take Leukast every evening.</li><li>&nbsp; &nbsp; It should be taken even when your child has no symptoms or if he/she has an acute asthma attack.</li></ul><p><strong>For children 6 months to 5 years of age:</strong></p><p>The recommended dose is one sachet of Leukast 4 mg granules to be taken by mouth each evening.</p><p>If your child is taking Leukast, be sure that your child does not take any other products that contain the same active ingredient, montelukast.</p><p><strong>How should I give Leukast granules to my child?</strong></p><p>This medicine is for oral use.</p><ul><li>&nbsp; &nbsp; &nbsp; Do not open the sachet until ready to use</li><li>&nbsp; &nbsp; &nbsp; &nbsp;Leukast granules can be given either:</li></ul><p>-&nbsp; directly in the mouth;</p><p>-&nbsp; OR mixed with a spoonful of cold or room temperature soft food (for example, applesauce, ice cream, carrots and rice).</p><ul><li>&nbsp; &nbsp; &nbsp; Mix all the contents of the Leukast granules into a spoonful of cold or room temperature soft food, taking care to see that the entire dose is mixed with the food. Be sure the child is given the entire spoonful of the granule/food mixture immediately (within 15 minutes).</li></ul><p>IMPORTANT: Never store any granule/food mixture for use at a later time.</p><ul><li>&nbsp; &nbsp; Leukast granules are not intended to be dissolved in liquid. However, your child may take liquids after swallowing the Leukast granules.</li><li>&nbsp; &nbsp; &nbsp; &nbsp;Leukast granules can be taken without regard to the timing of food intake</li></ul><p><strong>If your child takes more Leukast than he/she should</strong></p><p>Contact your child&rsquo;s doctor immediately for advice. There were no side effects reported in the majority of overdose reports. The most frequently occurring symptoms reported with overdose in adults and children included abdominal pain, sleepiness, thirst, headache, vomiting, and hyperactivity</p><p><strong>If you forget to give Leukast to your child</strong></p><p>Try to give Leukast as prescribed. However, if your child misses a dose, just resume theusual schedule of one sachet once daily.</p><p>Do not give a double dose to make up for a forgotten dose.</p><p><strong>If your child stops taking Leukast</strong></p><p><strong>&nbsp;</strong>Leukast can treat your child&rsquo;s asthma only if he/she continues taking it.</p><p>It is important for your child to continue taking Leukast for as long as your doctor prescribes. It will help control your child&rsquo;s asthma.</p><p>If you have any further questions on the use of this medicine, ask your child&rsquo;s doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>In clinical studies with Montelukast sodium 4 mg granules, the most commonly reported side effects (occurring in at least 1 of 100 patients and less than 1 of 10 paediatric patients treated) thought to be related to Montelukast sodium were:</p><ul><li>&nbsp; &nbsp; &nbsp; &nbsp;Diarrhea</li><li>&nbsp; &nbsp; &nbsp;Hyperactivity</li><li>&nbsp; &nbsp; &nbsp; Asthma</li><li>&nbsp; &nbsp; &nbsp; scaly and itchy skin</li><li>&nbsp; &nbsp; &nbsp; Rash</li></ul><p>Additionally, the following side effects were reported in clinical studies with either Montelukast sodium 10 mg film-coated tablets, 5 mg or 4 mg chewable tablets:</p><ul><li>&nbsp; &nbsp; &nbsp;Abdominal pain</li><li>&nbsp; &nbsp; &nbsp; &nbsp;Headache</li><li>&nbsp; &nbsp; &nbsp;Thirst</li></ul><p>These were usually mild and occurred at a greater frequency in patients treated with Montelukast than placebo (a pill containing no medication).</p><p>The frequency of possible side effects listed below is defined using the following convention:</p><p>Very common: may affect more than 1 in 10 people</p><p>Common: may affect up to 1 in 10 people</p><p>Uncommon: may affect up to 1 in 100 people</p><p>Rare: may affect up to 1 in 1,000 people</p><p>Very rare: may affect up to 1 in 10,000 people</p><p>Not known: frequency cannot be estimated from the available data</p><p>Additionally, while the medicine has been on the market, the following have been reported:</p><ul><li>&nbsp; &nbsp; &nbsp; Upper respiratory infection (Very common)</li><li>&nbsp; &nbsp; &nbsp; &nbsp;Increased bleeding tendency (Rare)</li><li>&nbsp; &nbsp; &nbsp; Allergic reactions including swelling of the face, lips, tongue, and/or throat which may cause difficulty in breathing or swallowing (Uncommon)</li><li>&nbsp; &nbsp; &nbsp; Behaviour and mood related changes [dream abnormalities, including nightmares, trouble sleeping, sleep walking, irritability, feeling anxious, restlessness, agitation including aggressive behaviour or hostility, depression (Uncommon); tremor, disturbance in attention, memory impairment (Rare); hallucinations, disorientation, suicidal thoughts and actions (Very rare)]</li><li>&nbsp; &nbsp; &nbsp; Dizziness, drowsiness, pins and needles/numbness, seizure (Uncommon)</li><li>&nbsp; &nbsp; &nbsp;Palpitations (Rare)</li><li>&nbsp; &nbsp; &nbsp;&nbsp;Nosebleed (Uncommon), swelling (inflammation) of the lungs (Very rare)</li><li>&nbsp; &nbsp; &nbsp; Diarrhoea, nausea, vomiting (Common); dry mouth, indigestion (Uncommon)</li><li>&nbsp; &nbsp; &nbsp; &nbsp;Hepatitis (inflammation of the liver) (Very rare)</li><li>&nbsp; &nbsp; &nbsp; Rash (Common); bruising, itching, hives (Uncommon); tender red lumps under the skin most commonly on your shins (erythema nodosum), severe skin reactions (erythema multiforme) that may occur without warning (Very rare)</li><li>&nbsp; &nbsp; &nbsp; &nbsp; Joint or muscle pain, muscle cramps (Uncommon)</li><li>&nbsp; &nbsp; &nbsp; Fever (Common); weakness/tiredness, feeling unwell, swelling (Uncommon)</li></ul><p>In asthmatic patients treated with montelukast, very rare cases of a combination of symptoms such as flu-like illness, pins and needles or numbness of arms and legs, worsening of pulmonary symptoms and/or rash (Churg-Strauss syndrome) have been reported. You must tell your doctor right away if your child gets one or more of these symptoms (see section 2).</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, healthcare provider or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 30&deg;C.</p><p>Do not use this medicine after the expiry date which is stated on the package after EXP. The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Montelukast sodium<br />The &nbsp;other &nbsp;ingredients &nbsp;are &nbsp;Mannitol &nbsp;200 &nbsp;SD, &nbsp;Hydroxy Propyl Cellulose LF and Absolute Alcohol<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Granules in sachet, White to off-white fine granules.
Pack size: 28 Sachets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road P.O. BOX 106229<br />Riyadh, 11666, Saudi Arabia<br />Tel: +966 11 2078172<br />Fax: +966 11 2078097<br /><strong>Manufacturer</strong><br />Jazeera Pharmaceutical Industries,<br />3rd industrial zone, Al Kharj Road P.O.Box 106229</p><p>&nbsp;Riyadh 11666<br />Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 3/2017; version number 1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ماهو ليوكاست</strong></p><p dir="RTL">ليوكاست هو مضاد مستقبلات الليكوترين الذي يمنع مواد تسمى يوكوترين.</p><p dir="RTL"><strong>كيفية عمل ليوكاست</strong></p><p dir="RTL">يوكوترين يسبب تضييق وتورم الممرات الهوائية في الرئتين. من خلال منع يوكوترين، ليوكاست يحسن أعراض الربو ويساعد على السيطرة على الربو.</p><p dir="RTL"><strong>متى يجب استعمال ليوكاست</strong></p><p dir="RTL">يصف الطبيب ليوكاست لطفلك لعلاج الربو، ولتجنب اعراض الربو خلال الليل والنهار .</p><ul dir="rtl"><li>&nbsp;يستخدم ليوكاست لعلاج المرضى الاطفال مابين 6 أشهر إلى 5 سنوات الذين لم تتم السيطرة بشكل كاف على الربو ويحتاجون لعلاج اضافي .</li><li>ليوكاست قد يتم استعماله كعلاج بديل للاستيرويدات القشرية التي يتم استنشاقها للأطفال من عمر سنتين إلى 5 سنوات الذين لم يسبق لهم إستعمال الاستروديات القشرية قريبا لعلاج الربو لديهم وأبدو أنهم غير قادرين على استعمال الستيوريدات المستنشقة.</li><li>يساعد ليوكاست أيضا على منع تضييق المجاري التنفسية الناجمة عن ممارسة الرياضة للاطفال من عمر سنتين وأكبر.</li></ul><p dir="RTL">سيقوم طبيبك بتحديد كيفية استخدام ليوكاست اعتمادا على أعراض وشدة ربو طفلك.</p><p dir="RTL"><strong>ماهو الربو ؟</strong></p><p dir="RTL">الربو هو مرض طويل الأمد</p><p dir="RTL">يتضمن الربو ما يلي:</p><ul dir="rtl"><li>&nbsp; &nbsp; صعوبة في التنفس بسبب ضيق الشعب الهوائية. هذا التضيق في الشعب الهوائية يتفاقم ويتحسن استجابة لظروف مختلفة .</li><li>&nbsp; &nbsp; مجاري الهواء الحساسة التي تتفاعل مع أشياء كثيرة، مثل دخان السجائر، حبوب اللقاح، الهواء البارد، أو ممارسة الرياضة .</li><li>&nbsp; &nbsp; تورم (التهاب) في بطانة الشعب الهوائية.</li></ul><p dir="RTL">وتشمل أعراض الربو: السعال، والتنفس، وضيق الصدر</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استخدام ليوكاست</strong></p><p dir="RTL">أخبر طبيبك عن أي مشاكل طبية أو حساسية لدى طفلك الآن أو قد حدثت في وقت سابق.</p><p dir="RTL"><strong>لا تستخدم ليوكاست لطفلك</strong><strong>:</strong></p><p dir="RTL">إذا كانت لديه / لديها حساسية من مونتلوكاست أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم &nbsp;6).</p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">تحدث مع طبيبك، الصيدلي، أو الممرض قبل استخدام ليوكاست:</p><ul dir="rtl"><li>&nbsp; &nbsp; إذا ساءت حالة الربو أو تنفس طفلك، أخبر طبيبك فورا.</li><li>&nbsp; &nbsp; &nbsp; ليوكاست عن طريق الفم ليس الغرض منه علاج نوبات الربو الحادة. إذا حدثت نوبة حادة، اتبع التعليمات التي قدمها لك طبيبك لطفلك. دائما احمل دواء الإنقاذ عن طريق الاستنشاق لطفلك في حالة حدوث نوبات الربو معك.</li><li>&nbsp; &nbsp; &nbsp; &nbsp;من المهم أن يأخذ طفلك جميع أدوية الربو الموصوفة من قبل الطبيب. يجب عدم استخدام ليوكاست بدلا من أدوية الربو الأخرى التي وصفها طبيبك لطفلك.</li><li>&nbsp; &nbsp; إذا كان طفلك يستعمل أدوية مضادة للربو، يجب أن تكون على علم وإدراك أنه إذا كان قد طور مجموعة من الأعراض مثل اعراض مشابهة للأنفلونزا أو أو أحس بوخز أو خدر في الذراعين أو الساقين أو تفاقم الأعراض الرئوية و / أو الطفح الجلدي, يجب عليك استشارة الطبيب.</li><li>&nbsp; &nbsp; &nbsp;يجب على طفلك عدم تناول أسيتيل- ساليسيليك أسيد (أسبرين) أو أدوية مضادة للالتهابات (تعرف أيضا باسم مضاد الالتهابات غير الستيرويدية) إذ أنها تجعل الربو يزداد سوءا.</li></ul><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;لا تعطي هذه الأدوية للأطفال أقل من 6 أشهر من العمر .</li><li>&nbsp; &nbsp; &nbsp; هناك أشكال مختلفة من هذا الدواء متوفر للمرضى الأطفال دون سن 18 سنة على أساس الفئة العمرية.</li></ul><p dir="RTL"><strong>الأدوية الأخرى و ليوكاست</strong></p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلي إذا كان طفلك قد اخذ مؤخرا ادوية، بما فيها تلك التي تم الحصول عليها دون وصفة طبية .</p><p dir="RTL">قد تؤثر بعض الأدوية على كيفية عمل دواء ليوكاست ، أو ان دواء ليوكاست قد يؤثر على كيفية عمل الأدوية الأخرى .</p><p dir="RTL">أخبر طبيبك إذا كان طفلك قد استعمل الأدوية التالية قبل البدء باستخدام ليوكاست :</p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;الفينوباربيتال (التي تستخدم لعلاج الصرع)</li><li>&nbsp; &nbsp; &nbsp;الفينيتوين (المستخدم لعلاج الصرع)</li><li>&nbsp; &nbsp; &nbsp;ريفامبيسين (المستخدمة لعلاج السل وبعض الأمراض الأخرى)</li></ul><p dir="RTL"><strong>ليوكاست مع الطعام والشراب</strong></p><p dir="RTL">يمكن تناول ليوكاست مع او بدون الطعام.</p><p dir="RTL"><strong>الحمل و الرضاعة</strong></p><p dir="RTL">هذا القسم لا ينطبق على حبيبات ليوكاست 4 ملغ حيث أنها مخصصة للاستخدام للأطفال من 6 أشهر إلى 5 سنوات من العمر.</p><p dir="RTL"><strong>تأثير ليوكاست على القيادة واستخدام الآلات</strong></p><p dir="RTL">هذا القسم لا ينطبق على حبيبات ليوكاست 4 ملغ حيث أنها مخصصة للاستخدام للأطفال من 6 أشهر إلى 5 سنوات من العمر.</p><p dir="RTL">ومع ذلك المعلومات التالية ذات صلة بالعنصر الفعال، مونتيلوكاست.</p><p dir="RTL">ليس من المتوقع أن يؤثر ليوكاست على قدرتك على قيادة السيارة أو تشغيل الآلات. ومع ذلك، قد تختلف استجابات الفرد للدواء. بعض الآثار الجانبية (مثل الدوخة والنعاس) التي تم الإبلاغ عنها نادرا جدا مع ليوكاست التي قد تؤثر على قدرة بعض المرضى على القيادة أو تشغيل الآلات.</p><p dir="RTL"><strong>يحتوي ليوكاست على مانيتول التي قد يكون لها تأثير ملين خفيف</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب دائما أن يأخذ طفلك هذا الدواء تماما كما أخبرك الطبيب أو الصيدلي. راجع طبيب طفلك أو الصيدلي إذا لم تكن متأكدا.</p><ul dir="rtl"><li>&nbsp; &nbsp;يعطى هذا الدواء للطفل تحت إشراف الكبار. يجب أن يأخذ طفلك ليوكاست كل مساء.</li><li>&nbsp; &nbsp; &nbsp;وينبغي أن يتناول طفلك ليوكاست حتى عندما يكون ليست لديه أي أعراض للربو أو نوبة الربو الحادة.</li></ul><p dir="RTL">للأطفال من 6 أشهر إلى 5 سنوات من العمر:</p><ul dir="rtl"><li>&nbsp; &nbsp; الجرعة الموصى بها هي كيس واحد من حبيبات ليوكاست 4 ملغ التي تؤخذ عن طريق الفم كل مساء.</li><li>&nbsp; &nbsp; &nbsp; إذا كان طفلك يأخذ ليوكاست، تأكد من أن طفلك لا يأخذ أي منتجات أخرى تحتوي على نفس العنصر النشط، مونتيلوكاست.</li></ul><p dir="RTL"><strong>كيف يمكنني إعطاء حبيبات ليوكاست لطفلي؟</strong></p><p dir="RTL">هذا الدواء هو للاستخدام عن طريق الفم.</p><ul dir="rtl"><li>&nbsp;لا تفتح الكيس حتى يصبح جاهز للاستخدام</li><li>&nbsp;حبيبات ليوكاست يمكن أن تعطى إما:</li></ul><p dir="RTL">- مباشرة عن طريق الفم.</p><p dir="RTL">- أو ممزوج مع ملعقة طعام بارد أو في درجة حرارة الغرفة (على سبيل المثال، التفاح، والآيس كريم والجزر والأرز).</p><ul dir="rtl"><li>تخلط حبيبات ليوكاست مع ملعقة طعام بارد أو في درجة حرارة الغرفة مع الحرص على أن يتم خلط الجرعة باكملها مع الطعام. تأكد من إعطاء الطفل ملعقة كاملة من خليط الحبيبات مع الطعام على الفور (في غضون 15 دقيقة).</li></ul><p dir="RTL">هام: لا تقم أبدا بتخزين أي خليط من الحبيبات / المواد الغذائية للاستخدام في وقت لاحق.</p><ul dir="rtl"><li>ليس الغرض من حبيبات ليوكاست أن تذوب في السائل. ومع ذلك، من الممكن أن يشرب طفلك سوائل بعد بلع حبيبات ليوكاست.</li><li>يمكن أن تؤخذ حبيبات ليوكاست بغض النظر عن توقيت تناول الطعام</li></ul><p dir="RTL"><strong>إذا تناول طفلك جرعة زائدة عن اللازم من ليوكاست</strong></p><p dir="RTL">اتصل بطبيب طفلك فورا للحصول على المشورة.</p><p dir="RTL">لم تذكر أي آثار جانبية في معظم تقارير الجرعة الزائدة. شملت الأعراض التي تحدث في أغلب الأحيان مع الجرعة الزائدة عند البالغين والأطفال : آلام في البطن، والنعاس، والعطش، والصداع، والتقيؤ، وفرط النشاط.</p><p dir="RTL"><strong>إذا كنت قد نسيت أن تعطي ليوكاست لطفلك</strong></p><p dir="RTL">حاول أن تعطي ليوكاست كما هو مقرر من الطبيب. على الرغم من ذلك اذا وجدت نفسك نسيت إعطاء طفلك الجرعة من ليوكاست، انتظر حتى وقت تناول الجرعة التالية في وقتها المعتاد من كيس واحدة في اليوم.</p><p dir="RTL">لا تأخذ جرعة مضاعفة للتعويض عن الجرعة المنسيه.</p><p dir="RTL"><strong>إذا توقف طفلك عن تناول ليوكاست</strong></p><p dir="RTL">تعالج حبيبات الليوكاست الربو عند طفلك فقط عندما تستمر بتناول هذه الأقراص.</p><p dir="RTL">من المهم لطفلك أن يستمر في تناول ليوكاست طالما أنه بوصفة الطبيب. اذ انه يساعد في السيطرة على الربو لطفلك.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا المنتج، ، يرجى استشارة طبيب طفلك او الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية يمكن لهذا الدواء ان يسبب اعراضا جانبية، وان لم تحصل لجميع المرضى. في الدراسات السريرية مع مونتلوكاست، اظهرت ان الآثار الجانبية الأكثر شيوعا (التي تحدث عند 1 على الأقل من 100 مريض، وأقل من 1 من 10 المرضى المعالجين) &nbsp;و يعتقد أن لها صلة بمونتلوكاست هي:</p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp; إسهال</li><li>&nbsp; &nbsp; &nbsp;فرط نشاط</li><li>&nbsp; &nbsp; &nbsp;الربو</li><li>&nbsp; &nbsp; &nbsp; قشور وحكة في الجلد</li><li>&nbsp; &nbsp; &nbsp; الطفح الجلدي</li></ul><p dir="RTL">بالإضافة إلى ذلك، تم الإبلاغ عن الآثار الجانبية التالية في الدراسات السريرية مع إما مونتلوكاست أقراص مغلفة أو أقراص مضغ:</p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;وجع بطن</li><li>&nbsp; &nbsp; &nbsp; &nbsp;صداع الراس</li><li>&nbsp; &nbsp; العطش</li></ul><p dir="RTL">عادة ما تكون هذه الاثار خفيفة وحصلت بشكل أكبر عند المرضى المعالجون بليوكاست بالمقارنة مع المرضى الذين عولجوا بأقراص وهمية (الأقراص المستخدمة لا تحتوي على الدواء).</p><p dir="RTL">يتم تعريف تردد الاثار الجانبية المحتملة المدرجة أدناه باستخدام الاصطلاحات التالية:</p><p dir="RTL">شائع جدا : (قد تؤثر على أكثر من 1 في 10 أشخاص).</p><p dir="RTL">شائع :(قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص)</p><p dir="RTL">غير شائع : (قد يؤثر على ما يصل إلى 1 من 100 شخص)</p><p dir="RTL">نادر: (قد تؤثر على ما يصل إلى 1 في 1000 شخص)</p><p dir="RTL">نادرة جدا : (قد تؤثر على ما يصل إلى 1 من 10،000 شخص)</p><p dir="RTL">غير معروف: لا يمكن تقدير التردد من البيانات المتاحة</p><p dir="RTL"><strong>تم الابلاغ عن الآثار الجانبية التالية خلال فترة تسويق الدواء</strong></p><ul dir="rtl"><li>&nbsp; &nbsp; &nbsp;عدوى الجهاز التنفسي العلوي (شائع جدا)</li><li>&nbsp; &nbsp; &nbsp; زيادة القابلية للنزيف ( نادر)</li><li>&nbsp; &nbsp; &nbsp; ردود فعل تحسسيه بما في ذلك تورم في الوجه والشفتين واللسان، و / أو الحلق مما قد يسبب صعوبة في التنفس أو البلع (غير شائع)</li><li>&nbsp; &nbsp; &nbsp; &nbsp;تغييرات سلوكيه ومزاجية [حلم غير طبيعية، بما في ذلك الكوابيس، واضطرابات النوم، والمشي أثناء النوم، والتهيج، والشعور بالقلق، والأرق، والتهيج بما في ذلك السلوك العدواني أو العداء والاكتئاب (غير شائع). رجفان، تشتت الانتباه، اضطراب في الذاكرة (نادر)؛ هلوسة، دوار، افكار واعمال انتحارية (نادر جدا).</li><li>&nbsp; &nbsp; &nbsp; دوار، والنعاس، ووخز / تنميل، وتشنجات (غير شائع)</li><li>&nbsp; &nbsp; &nbsp; تسارع بضربات القلب (نادر)</li><li>&nbsp; &nbsp; &nbsp; نزيف انفي (الرعاف) &nbsp;(غير شائع) &nbsp;تورم (التهاب) الرئتين (نادر جدا)</li><li>&nbsp; &nbsp; &nbsp; &nbsp;اسهال، غثيان، استفراغ (شائع)؛ جفاف الفم، عسر الهضم (غير شائع)</li><li>&nbsp; &nbsp; &nbsp;التهاب الكبد (نادر جدا)</li><li>&nbsp; &nbsp; &nbsp; &nbsp;تحسس (شائع)؛ كدمات، والحكة، و الشرى (غير شائع)؛ انتفاخ كتل حمراء تحت الجلد اكثر شيوعا على السيقان (حمامي عقدية)،رد فعل تحسسي وخيم للجلد (حمامي عديدة الأشكال) التي قد تحدث دون سابق إنذار (نادر جدا).</li><li>&nbsp; &nbsp; &nbsp; ألم في العضلات او المفاصل، وتشنجات العضلات (غير شائع)</li><li>&nbsp; &nbsp; &nbsp;الضعف / التعب، والشعور بالإعياء، وتورم (غير شائع)</li></ul><p dir="RTL">في مرضى الربو الذين يعالجون بمونتيليوكاست، تم الإبلاغ عن حالات نادرة جدا عن مجموعة من الأعراض مثل الأعراض الشبيهة بمرض الإنفلونزا، أوالأحساس بوخز أو خدر في الذراعين أو الساقين،أو تفاقمت أعراض الربو الرئوية، أوفي حال ظهور طفح جلدي (متلازمة شيرغ ستروس). يجب عليك إخبار الطبيب على الفور إذا حصلت لك واحد أو أكثر من هذه الأعراض.</p><p dir="RTL">يرجى الاتصال بالطبيب، مقدم الرعاية الصحية، أو الصيدلي في حال اصبحت أي من الآثار الجانبية أكثر سوءاً أو في حال ظهور أية آثار جانبية جديدة لم تذكر في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li>&nbsp; &nbsp; &nbsp; احفظ هذا الدواء بعيد اً عن مرأى ومتناول الأطفال.</li><li>&nbsp; &nbsp; &nbsp; لا تحفظ الدواء عند درجة حرارة أعلى من 30 &deg; مئوية.</li><li>&nbsp; &nbsp; &nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</li><li>&nbsp; &nbsp; &nbsp;لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي مونتلوكاست الصوديوم والتي تكافئ 4 ملغ من مونتيليوكاست</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي مانيتول و هيدروكسي بروبيل السليلوز</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>حبيبات بيضاء اللون<br />حجم العبوة: 28 كيس</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL">الجزيرة للصناعات الدوائية (JPI )</p><p dir="RTL">الرياض، المملكة العربية السعودية، الرياض 11666 ، صندوق البريد 106229</p><p dir="RTL">رقم الهاتف: 8172 - 207 - 11 - 966 +</p><p dir="RTL">فاكس: 8097 - 207 - 11 - 966 +</p><p>البريد الإلكتروني : &nbsp;<u>medical@jpi.com.sa</u></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تمت مراجعة هذه النشرة بتاريخ 3/2017 ، رقم النسخة: 1.0 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Leukast ® 4 mg Granules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One sachet of granules contains montelukast sodium, which is equivalent to 4 mg montelukast.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Granules in sachet, White to off-white fine granules.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Leukast is indicated in the treatment of asthma as add-on therapy in those 6 months to 5 year old patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom &ldquo;as-needed&rdquo; short acting &beta;-agonists provide inadequate clinical control of asthma.</p><p>Leukast may also be an alternative treatment option to low-dose inhaled corticosteroids for 2 to 5 year old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.2).</p><p>Leukast is also indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>This medicinal product is to be given to a child under adult supervision. The recommended dose for pediatric patients 6 months to 5 years of age is one sachet of 4 mg granules daily to be taken in the evening. No dosage adjustment within this age group is necessary. Efficacy data from clinical trials in pediatric patients 6 months to 2 years of age with persistent asthma are limited. Patients should be evaluated after 2 to 4 weeks for response to montelukast treatment.</p><p>Treatment should be discontinued if a lack of response is observed. The montelukast sodium 4 mg granules formulation is not recommended below 6 months of age.</p><p><em>Administration of Leukast granules:</em></p><p>montelukast sodium granules can be administered either directly in the mouth, or mixed with a spoonful of cold or room temperature soft food (e.g., applesauce, ice cream, carrots and rice). The sachet should not be opened until ready to use. After opening the sachet, the full dose of montelukast sodium granules must be administered immediately (within 15 minutes). If mixed with food, montelukast sodium granules must not be stored for future use. montelukast sodium granules are not intended to be dissolved in liquid for administration. However, liquids may be taken subsequent to administration. montelukast sodium granules can be administered without regard to the timing of food ingestion.</p><p><u>General recommendations</u></p><p>The therapeutic effect of montelukast sodium on parameters of asthma control occurs within one day. Patients should be advised to continue taking Leukast even if their asthma is under control, as well as during periods of worsening asthma.</p><p>No dosage adjustment is necessary for patients with renal insufficiency, or mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The dosage is the same for both male and female patients.</p><p><u>Leukast as an alternative treatment option to low-dose inhaled corticosteroids for mild,</u> <u>persistent asthma</u></p><p>Montelukast is not recommended as monotherapy in patients with moderate persistent asthma. The use of montelukast as an alternative treatment option to low-dose inhaled corticosteroids for children 2 to 5 years old with mild persistent asthma should only be considered for patients who do not have a recent history of serious asthma attacks that required oral corticosteroid use and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.1). Mild persistent asthma is defined as asthma symptoms more than once a week but less than once a day, nocturnal symptoms more than twice a month but less than once a week, normal lung function between episodes. If satisfactory control of asthma is not achieved at follow-up (usually within one month), the need for an additional or different anti-inflammatory therapy based on the step system for asthma therapy should be evaluated. Patients should be periodically evaluated for their asthma control.</p><p><u>Leukast as prophylaxis of asthma for 2 to 5 year old patients in whom the predominant</u> <u>component is exercise-induced bronchoconstriction</u></p><p>In 2 to 5 year old patients, exercise-induced bronchoconstriction may be the predominant manifestation of persistent asthma that requires treatment with inhaled corticosteroids. Patients should be evaluated after 2 to 4 weeks of treatment with montelukast. If satisfactory response is not achieved, an additional or different therapy should be considered.</p><p><u>Therapy with Leukast in relation to other treatments for asthma</u></p><p>When treatment with Montelukast is used as add-on therapy to inhaled corticosteroids, Montelukast should not be abruptly substituted for inhaled corticosteroids (see section 4.4). 10 mg film-coated tablets are available for adults and adolescents 15 years of age and older.</p><p><em>Pediatric population</em></p><p>Do not give montelukast sodium 4 mg granules to children less than 6 months of age. The safety and efficacy of montelukast sodium 4 mg granules in children less than 6 months of age has not been established.</p><p>5 mg chewable tablets are available for pediatric patients 6 to 14 years of age.</p><p>4 mg chewable tablets are available as an alternative formulation for pediatric patients 2 to 5 years of age.</p><p><u>Method of administration</u></p><p>Oral use.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The diagnosis of persistent asthma in very young children (6 months &ndash; 2 years) should be established by a pediatrician or pulmonologist.</p><p>Patients should be advised never to use oral montelukast to treat acute asthma attacks and to keep their usual appropriate rescue medication for this purpose readily available. If an acute attack occurs, a short-acting inhaled &beta;-agonist should be used. Patients should seek their doctors&#39; advice as soon as possible if they need more inhalations of short-acting &beta;-agonists than usual.</p><p>Montelukast should not be abruptly substituted for inhaled or oral corticosteroids.</p><p>There are no data demonstrating that oral corticosteroids can be reduced when montelukast is given concomitantly.</p><p>In rare cases, patients on therapy with anti-asthma agents including montelukast may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition which is often treated with systemic corticosteroid therapy. These cases have been sometimes associated with the reduction or withdrawal of oral corticosteroid therapy. Although a causal relationship with leukotriene receptor antagonism has not been established, physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients.</p><p>Patients who develop these symptoms should be reassessed and their treatment regimens evaluated.</p><p>Treatment with montelukast does not alter the need for patients with aspirin-sensitive asthma to avoid taking aspirin and other non-steroidal anti-inflammatory drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medicinal products: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol/norethindrone 35/1), terfenadine, digoxin and warfarin.</p><p>The area under the plasma concentration curve (AUC) for montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. Since montelukast is metabolised by CYP 3A4, 2C8, and 2C9, caution should be exercised, particularly in children, when montelukast is coadministered with inducers of CYP 3A4, 2C8, and 2C9, such as phenytoin, phenobarbital and rifampicin.</p><p>In vitro studies have shown that montelukast is a potent inhibitor of CYP 2C8. However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of medicinal products primarily metabolised by CYP 2C8) demonstrated that montelukast does not inhibit CYP 2C8 in vivo. Therefore, montelukast is not anticipated to markedly alter the metabolism of medicinal products metabolised by this enzyme (e.g., paclitaxel, rosiglitazone, and repaglinide).</p><p>In vitro studies have shown that montelukast is a substrate of CYP 2C8, and to a less significant extent, of 2C9, and 3A4. In a clinical drug-drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) gemfibrozil increased the systemic exposure of montelukast by 4.4-fold. No routine dosage adjustment of montelukast is required upon co- administration with gemfibrozil or other potent inhibitors of CYP 2C8, but the physician should be aware of the potential for an increase in adverse reactions.</p><p>Based on in vitro data, clinically important drug interactions with less potent inhibitors of CYP 2C8 (e.g., trimethoprim) are not anticipated. Co-administration of montelukast with itraconazole, a strong inhibitor of CYP 3A4, resulted in no significant increase in the systemic exposure of montelukast.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Animal studies do not indicate harmful effects with respect to effects on pregnancy or embryonal/foetal development.</p><p>Limited data from available pregnancy databases do not suggest a causal relationship between montelukast and malformations (i.e. limb defects) that have been rarely reported in worldwide post-marketing experience.</p><p>Leukast may be used during pregnancy only if it is considered to be clearly essential.</p><p><u>Breast-feeding</u></p><p>Studies in rats have shown that montelukast is excreted in milk (see section 5.3). It is unknown whether montelukast/metabolites are excreted in human milk.</p><p>Leukast may be used in breast-feeding mothers only if it is considered to be clearly essential</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast has no or negligible influence on the ability to drive and use machines. However, individuals have reported drowsiness or dizziness.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Montelukast has been evaluated in clinical studies in patients with persistent asthma as follows:</p><ul><li>&nbsp; &nbsp; &nbsp; &nbsp;10 mg film-coated tablets in approximately 4,000 adult and adolescent patients 15 years of age and older</li><li>&nbsp; &nbsp; &nbsp; 5 mg chewable tablets in approximately 1,750 pediatric patients 6 to 14 years of age</li><li>&nbsp; &nbsp; &nbsp; &nbsp; 4 mg chewable tablets in 851 pediatric patients 2 to 5 years of age, and</li><li>&nbsp; &nbsp; &nbsp; 4 mg granules in 175 pediatric patients 6 months to 2 years of age.</li><li>&nbsp; &nbsp; &nbsp; &nbsp;Montelukast has been evaluated in a clinical study in patients with intermittent asthma as follows:</li><li>&nbsp; &nbsp; &nbsp; &nbsp;4 mg granules and chewable tablets in 1,038 pediatric patients 6 months to 5 years of age</li></ul><p>The following drug-related adverse reactions in clinical studies were reported commonly (&ge;1/100 to &lt;1/10) in patients treated with montelukast and at a greater incidence than in patients treated with placebo:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body System Class</strong></p></td><td style="vertical-align:top"><p><strong>Adult and Adolescent Patients 15 years and older (two 12-week studies; n=795)</strong></p></td><td style="vertical-align:top"><p><strong>Pediatric Patients 6 to 14 years old</strong></p><p><strong>(one 8-week study; n=201)</strong></p><p><strong>(two 56-week studies; n=615)</strong></p></td><td style="vertical-align:top"><p><strong>Pediatric Patients 2 to 5 years old (one 12-week study; n=461) (one 48-week study; n=278)</strong></p></td><td style="vertical-align:top"><p><strong>Pediatric Patients 6 months up to 2 years old</strong></p><p><strong>(one 6-week study; n=175)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hyperkinesia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic, and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>asthma</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>abdominal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abdominal pain</p></td><td style="vertical-align:top"><p>diarrhea</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>eczematous dermatitis, rash</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>thirst</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>With prolonged treatment in clinical trials with a limited number of patients for up to 2 years for adults, and up to 12 months for pediatric patients 6 to 14 years of age, the safety profile did not change.</p><p>Cumulatively, 502 pediatric patients 2 to 5 years of age were treated with montelukast for at least 3 months, 338 for 6 months or longer, and 534 patients for 12 months or longer. With prolonged treatment, the safety profile did not change in these patients either.</p><p>The safety profile in pediatric patients 6 months to 2 years of age did not change with treatment up to 3 months.</p><p><u>Tabulated list of Adverse Reactions</u></p><p>Adverse reactions reported in post-marketing use are listed, by System Organ Class and specific Adverse Reactions, in the table below. Frequency Categories were estimated based on relevant clinical trials.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Reactions</strong></p></td><td style="vertical-align:top"><p><strong>Frequency Category*</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>upper respiratory infection<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>increased bleeding tendency</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>hypersensitivity reactions including anaphylaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>hepatic eosinophilic infiltration</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>dream abnormalities including nightmares, insomnia, somnambulism, anxiety, agitation including aggressive behaviour or hostility, depression, psychomotor hyperactivity (including</p></td><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>irritability, restlessness, tremor<sup>&sect;</sup> )</p></td></tr><tr><td style="vertical-align:top"><p>disturbance in attention, memory impairment</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>hallucinations, disorientation, suicidal thinking and behaviour (suicidality)</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>dizziness, drowsiness, paraesthesia/hypoesthesia, seizure</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>palpitations</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>epistaxis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Churg-Strauss Syndrome (CSS) (see section 4.4)</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>pulmonary eosinophilia</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>diarrhea&Dagger;, nausea&Dagger;, vomiting&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>dry mouth, dyspepsia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>elevated levels of serum transaminases (ALT, AST)</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>hepatitis (including cholestatic, hepatocellular, and mixed-pattern liver injury).</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>rash&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>bruising, urticaria, pruritus</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>angiooedema</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>erythema nodosum, erythema multiforme</p></td><td style="vertical-align:top"><p>Very Rare</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>arthralgia, myalgia including muscle cramps</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>pyrexia&Dagger;</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>asthenia/fatigue, malaise, oedema</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* Frequency Category: Defined for each Adverse Reaction by the incidence reported in the clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1,000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1,000), Very Rare (&lt;1/10,000).</p><p>&dagger; This adverse experience, reported as Very Common in the patients who received montelukast, was also reported as Very Common in the patients who received placebo in clinical trials.</p><p>&Dagger; This adverse experience, reported as Common in the patients who received montelukast, was also reported as Common in the patients who received placebo in clinical trials.</p><p>&sect; Frequency Category: Rare</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after&nbsp; authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>&nbsp; &nbsp; &nbsp;<strong>Saudi Arabia</strong></li><li>&nbsp; &nbsp; &nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</li><li>&nbsp; &nbsp; &nbsp;Fax: +966-11-205-7662</li><li>&nbsp; &nbsp; &nbsp; &nbsp;Toll free: 800-249-0000</li><li>&nbsp; &nbsp; &nbsp; &nbsp;Phone No.: +966-11-2038222, Exts: 2317-2334-2340-2353-2354-2356.</li><li>&nbsp; &nbsp; &nbsp; &nbsp;Email: <u>npc.drug@sfda.gov.sa</u></li><li>&nbsp; &nbsp; &nbsp; &nbsp;Website:<u> www.sfda.gov.sa/npc</u></li><li>Other GCC States:</li></ul><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In chronic asthma studies, montelukast has been administered at doses up to 200 mg/day to adult patients for 22 weeks and in short term studies, up to 900 mg/day to patients for approximately one week without clinically important adverse experiences.</p><p>There have been reports of acute overdose in post-marketing experience and clinical studies with montelukast. These include reports in adults and children with a dose as high as 1,000 mg (approximately 61 mg/kg in a 42 month old child). The clinical and laboratory findings observed were consistent with the safety profile in adults and pediatric patients. There were no adverse experiences in the majority of overdose reports.</p><p><u>Symptoms of overdose</u></p><p>The most frequently occurring adverse experiences were consistent with the safety profile of montelukast and included abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity.</p><p><u>Management of overdose</u></p><p>No specific information is available on the treatment of overdose with montelukast. It is not known whether montelukast is dialysable by peritoneal- or haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Leukotriene receptor antagonist</p><p>ATC-code: R03D C03</p><p><u>Mechanism of action</u></p><p>The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory eicosanoids released from various cells including mast cells and eosinophils. These important pro-asthmatic mediators bind to cysteinyl leukotriene receptors (CysLT) found in the human airway and cause airway actions, including bronchoconstriction, mucous secretion, vascular permeability, and eosinophil recruitment.</p><p><u>Pharmacodynamic effects</u></p><p>Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. In clinical studies, montelukast inhibits bronchoconstriction due to inhaled LTD4 at doses as low as 5 mg. Bronchodilation was observed within 2 hours of oral administration. The bronchodilation effect caused by a &beta;-agonist was additive to that caused by montelukast. Treatment with montelukast inhibited both early- and late-phase bronchoconstriction due to antigen challenge. Montelukast, compared with placebo, decreased peripheral blood eosinophils in adult and pediatric patients. In a separate study, treatment with montelukast significantly decreased eosinophils in the airways (as measured in sputum). In adult and pediatric patients 2 to 14 years of age, montelukast, compared with placebo, decreased peripheral blood eosinophils while improving clinical asthma control.</p><p><u>Clinical efficacy and safety</u></p><p>In studies in adults, montelukast, 10 mg once daily, compared with placebo, demonstrated significant improvements in morning FEV1 (10.4% vs 2.7% change from baseline), AM peak expiratory flow rate (PEFR) (24.5 L/min vs 3.3 L/min change from baseline), and significant decrease in total &beta;-agonist use (-26.1% vs -4.6% change from baseline). Improvement in patient- reported daytime and nighttime asthma symptoms scores was significantly better than placebo.</p><p>Studies in adults demonstrated the ability of montelukast to add to the clinical effect of inhaled corticosteroid (% change from baseline for inhaled beclomethasone plus montelukast vs beclomethasone, respectively for FEV1: 5.43% vs 1.04%; &beta;-agonist use: -8.70% vs 2.64%). Compared with inhaled beclomethasone (200 &mu;g twice daily with a spacer device), montelukast demonstrated a more rapid initial response, although over the 12-week study, beclomethasone provided a greater average treatment effect (% change from baseline for montelukast vs beclomethasone, respectively for FEV1: 7.49% vs 13.3%; &beta;-agonist use: -28.28% vs -43.89%). However, compared with beclomethasone, a high percentage of patients treated with montelukast achieved similar clinical responses (e.g., 50% of patients treated with beclomethasone achieved an improvement in FEV1 of approximately 11% or more over baseline while approximately 42% of patients treated with montelukast achieved the same response).</p><p>In an 8-week study in pediatric patients 6 to 14 years of age, montelukast 5 mg once daily, compared with placebo, significantly improved respiratory function (FEV1 8.71% vs 4.16% change from baseline; AM PEFR 27.9 L/min vs 17.8 L/min change from baseline) and decreased &rdquo;as-needed&rdquo; &beta;-agonist use (-11.7% vs +8.2% change from baseline).</p><p>In a 12-month study comparing the efficacy of montelukast to inhaled fluticasone on asthma control in pediatric patients 6 to 14 years of age with mild persistent asthma, montelukast was non-inferior to fluticasone in increasing the percentage of asthma rescue-free days (RFDs), the primary endpoint. Averaged over the 12-month treatment period, the percentage of asthma RFDs increased from 61.6 to 84.0 in the montelukast group and from 60.9 to 86.7 in the fluticasone group. The between group difference in LS mean increase in the percentage of asthma RFDs was statistically significant (-2.8 with a 95% CI of -4.7, -0.9), but within the limit predefined to be clinically not inferior. Both montelukast and fluticasone also improved asthma control on secondary variables assessed over the 12 month treatment period:</p><p>FEV1 increased from 1.83 L to 2.09 L in the montelukast group and from 1.85 L to 2.14 L in the fluticasone group. The between-group difference in LS mean increase in FEV1 was -0.02 L with a 95% CI of -0.06, 0.02. The mean increase from baseline in % predicted FEV1 was 0.6% in the montelukast treatment group, and 2.7% in the fluticasone treatment group. The difference in LS means for the change from baseline in the % predicted FEV1 was significant: -2.2% with a 95% CI of -3.6, -0.7.</p><p>The percentage of days with &beta;-agonist use decreased from 38.0 to 15.4 in the montelukast group, and from 38.5 to 12.8 in the fluticasone group. The between group difference in LS means for the percentage of days with &beta;-agonist use was significant: 2.7 with a 95% CI of 0.9, 4.5.</p><p>The percentage of patients with an asthma attack (an asthma attack being defined as a period of worsening asthma that required treatment with oral steroids, an unscheduled visit to the doctor&#39;s office, an emergency room visit, or hospitalisation) was 32.2 in the montelukast group and 25.6 in the fluticasone group; the odds ratio (95% CI) being significant: equal to 1.38 (1.04, 1.84).</p><p>The percentage of patients with systemic (mainly oral) corticosteroid use during the study period was 17.8% in the montelukast group and 10.5% in the fluticasone group. The between group difference in LS means was significant: 7.3% with a 95% CI of 2.9; 11.7.</p><p>In a 12-week, placebo-controlled study in pediatric patients 2 to 5 years of age, montelukast 4 mg once daily improved parameters of asthma control compared with placebo irrespective of concomitant controller therapy (inhaled/nebulised corticosteroids or inhaled/nebulised sodium cromoglycate). Sixty percent of patients were not on any other controller therapy. Montelukast improved daytime symptoms (including coughing, wheezing, trouble breathing and activity limitation) and nighttime symptoms compared with placebo. Montelukast also decreased &rdquo;as-needed&ldquo; &beta;-agonist use and corticosteroid rescue for worsening asthma compared with placebo. Patients receiving montelukast had more days without asthma than those receiving placebo. A treatment effect was achieved after the first dose.</p><p>In a 12-month, placebo-controlled study in pediatric patients 2 to 5 years of age with mild asthma and episodic exacerbations, montelukast 4 mg once daily significantly (p&le; 0.001) reduced the yearly rate of asthma exacerbation episodes (EE) compared with placebo (1.60 EE vs. 2.34 EE, respectively), [EE defined as &ge; 3 consecutive days with daytime symptoms requiring &beta;-agonist use, or corticosteroids (oral or inhaled), or hospitalization for asthma]. The percentage reduction in yearly EE rate was 31.9%, with a 95% CI of 16.9, 44.1.</p><p>In a placebo-controlled study in pediatric patients 6 months to 5 years of age who had intermittent asthma but did not have persistent asthma, treatment with montelukast was administered over a 12-month period, either as a once-daily 4 mg regimen or as a series of 12- day courses that each were started when an episode of intermittent symptoms began. No significant difference was observed between patients treated with montelukast 4 mg or placebo in the number of asthma episodes culminating in an asthma attack, defined as an asthma episode requiring utilization of health-care resources such as an unscheduled visit to a doctor&#39;s office, emergency room, or hospital; or treatment with oral, intravenous, or intramuscular corticosteroid.</p><p>Efficacy of montelukast is supported in pediatric patients 6 months to 2 years of age by extrapolation from the demonstrated efficacy in patients 2 years of age and older with asthma, and is based on similar pharmacokinetic data, as well as the assumption that the disease course, pathophysiology and the medicinal products&#39;s effect are substantially similar among these populations.</p><p>Significant reduction of exercise-induced bronchoconstriction (EIB) was demonstrated in a 12- week study in adults (maximal fall in FEV1 22.33% for montelukast vs 32.40% for placebo; time to recovery to within 5% of baseline FEV1 44.22 min vs 60.64 min). This effect was consistent throughout the 12-week study period. Reduction in EIB was also demonstrated in a short term study in pediatric patients 6 to 14 years of age (maximal fall in FEV1 18.27% vs 26.11%; time to recovery to within 5% of baseline FEV1 17.76 min vs 27.98 min). The effect in both studies was demonstrated at the end of the once-daily dosing interval.</p><p>In aspirin-sensitive asthmatic patients receiving concomitant inhaled and/or oral corticosteroids, treatment with montelukast, compared with placebo, resulted in significant improvement in asthma control (FEV1 8.55% vs -1.74% change from baseline and decrease in total &beta;-agonist use -27.78% vs 2.09% change from baseline).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Montelukast is rapidly absorbed following oral administration. For the 10 mg film-coated tablet, the mean peak plasma concentration (C<sub>max</sub>) is achieved 3 hours (T<sub>max</sub>) after administration in adults in the fasted state. The mean oral bioavailability is 64%. The oral bioavailability and Cmax are not influenced by a standard meal. Safety and efficacy were demonstrated in clinical trials where the 10 mg film-coated tablet was administered without regard to the timing of food ingestion.</p><p>For the 5 mg chewable tablet, the C<sub>max</sub> is achieved in 2 hours after administration in adults in the fasted state. The mean oral bioavailability is 73% and is decreased to 63% by a standard meal.</p><p>After administration of the 4 mg chewable tablet to pediatric patients 2 to 5 years of age in the fasted state, C<sub>max</sub> is achieved 2 hours after administration. The mean C<sub>max</sub> is 66% higher while mean C<sub>min</sub> is lower than in adults receiving a 10 mg tablet.</p><p>The 4 mg granule formulation is bioequivalent to the 4 mg chewable tablet when administered to adults in the fasted state. In pediatric patients 6 months to 2 years of age, C<sub>max</sub> is achieved 2 hours after administration of the 4 mg granules formulation. C<sub>max</sub> is nearly 2-fold greater than in adults receiving a 10 mg tablet. The co-administration of applesauce or a high-fat standard meal with the granule formulation did not have a clinically meaningful effect on the pharmacokinetics of montelukast as determined by AUC (1225.7 vs 1223.1 ng.hr/mL with and without applesauce, respectively, and 1191.8 vs 1148.5 ng.hr/mL with and without a high-fat standard meal, respectively).</p><p><u>Distribution</u></p><p>Montelukast is more than 99% bound to plasma proteins. The steady-state volume of distribution of montelukast averages 8-11 litres. Studies in rats with radiolabelled montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabelled material at 24 hours post-dose were minimal in all other tissues.</p><p><u>Biotransformation</u></p><p>Montelukast is extensively metabolised. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and children.</p><p>Cytochrome P450 2C8 is the major enzyme in the metabolism of montelukast. Additionally CYP 3A4 and 2C9 may have a minor contribution, although itraconazole, an inhibitor of CYP 3A4, was shown not to change pharmacokinetic variables of montelukast in healthy-subjects that received 10 mg montelukast daily. Based on in vitro results in human liver microsomes, therapeutic plasma concentrations of montelukast do not inhibit cytochromes P450 3A4, 2C9, 1A2, 2A6, 2C19, or 2D6. The contribution of metabolites to the therapeutic effect of montelukast is minimal.</p><p><u>Elimination</u></p><p>The plasma clearance of montelukast averages 45 ml/min in healthy adults. Following an oral dose of radiolabelled montelukast, 86% of the radioactivity was recovered in 5-day faecal collections and&nbsp; &lt;0.2% was recovered in urine. Coupled&nbsp; with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.</p><p><u>Characteristics in patients</u></p><p>No dosage adjustment is necessary for the elderly or mild to moderate hepatic insufficiency. Studies in patients with renal impairment have not been undertaken. Because montelukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment. There are no data on the pharmacokinetics of montelukast in patients with severe hepatic insufficiency (Child-Pugh score &gt;9).</p><p>With high doses of montelukast (20- and 60-fold the recommended adult dose), a decrease in plasma theophylline concentration was observed. This effect was not seen at the recommended dose of 10 mg once daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In animal toxicity studies, minor serum biochemical alterations in ALT, glucose, phosphorus and triglycerides were observed which were transient in nature. The signs of toxicity in animals were increased excretion of saliva, gastrointestinal symptoms, loose stools and ion imbalance. These occurred at dosages which provided &gt;17-fold the systemic exposure seen at the clinical dosage. In monkeys, the adverse effects appeared at doses from 150 mg/kg/day (&gt;232-fold the systemic exposure seen at the clinical dose). In animal studies, montelukast did not affect fertility or reproductive performance at systemic exposure exceeding the clinical systemic exposure by greater than 24-fold. A slight decrease in pup body weight was noted in the female fertility study in rats at 200 mg/kg/day (&gt;69-fold the clinical systemic exposure). In studies in rabbits, a higher incidence of incomplete ossification, compared with concurrent control animals, was seen at systemic exposure &gt;24-fold the clinical systemic exposure seen at the clinical dose. No abnormalities were seen in rats. Montelukast has been shown to cross the placental barrier and is excreted in breast milk of animals.</p><p>No deaths occurred following a single oral administration of montelukast sodium at doses up to 5,000 mg/kg in mice and rats (15,000 mg/m2 and 30,000 mg/m2 in mice and rats, respectively), the maximum dose tested. This dose is equivalent to 25,000 times the recommended daily adult human dose (based on an adult patient weight of 50 kg).</p><p>Montelukast was determined not to be phototoxic in mice for UVA, UVB or visible light spectra at doses up to 500 mg/kg/day (approximately &gt;200-fold based on systemic exposure).</p><p>Montelukast was neither mutagenic in in vitro and in vivo tests nor tumorigenic in rodent species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol 200 SD<br />Hydroxy Propyl Cellulose LF<br />Absolute Alcohol</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C. Store in the original package in order to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Packaged in PE/ALU/PE Foil 23/20/30 mic 128 MM</p><p>each pack contains 28 sachets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries (JPI)
Al‐Kharj Road, Third Industrial Zone
Riyadh, Saudi Arabia,
11666 Riyadh, P.O.Box 106229
Tel: +966 11 2078172
Fax: +966 11 2078097
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                27 March 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>